StemCell Therapy

HOUSTON--(BUSINESS WIRE)--Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced it is expanding its leadership team with the C-suite appointments of Jim Wingrove, Ph.D., as Chief Scientific Officer and David H. Ledbetter, Ph.D., as Chief Clinical Officer. Jonathan Roberts has been awarded the title of Chief Growth Officer.

We are thrilled to welcome Jim and David to the Dascena executive leadership team. In addition, Jonathan has earned this promotion through his leadership and significant contributions in helping advance Dascena to where we are today. As we build out our predictive algorithm roadmap, they each will play an integral role in our future success, said Ritankar Das, Chief Executive Officer of Dascena. Jims expertise in research and lab leadership will position Dascena for significant growth and execution in diagnostics and overall scientific strategy. Davids disciplined clinical strategy and research experience will be essential as we continue to explore the application of our algorithms and the impact they may have on healthcare systems and patients around the globe.

Jim is responsible for the management of Dascenas R&D and CLIA labs, as well as for guiding overall scientific strategy. Jim brings over 25 years of experience in molecular genetics and genomics. Prior to Dascena, Jim was Vice President of R&D at DotLab, where he established the company's R&D and CLIA labs. Prior to DotLab, Jim was Vice President of technical operations at CardioDx, where he was a co-inventor of the company's lead diagnostic product and led multiple groups, including R&D and the company's CLIA/CAP/NYS lab. Jim was a Life Science Research Foundation Fellow in the biochemistry and biophysics department at UCSF and completed his doctoral research in biochemistry at UCLA. He is an author of numerous scientific publications, including articles in Cell, Science and Nature.

David is a clinical strategy leader at Dascena focusing on new products, health systems partnerships and research. David joins Dascena from Geisinger where he was the founding Chief Scientific Officer and Executive Vice President and built one of the largest genomics and precision health programs in the world. Prior to Geisinger, David was a professor of human genetics at Emory University School of Medicine. Earlier in his career, he was a professor and founding chair in the department of human genetics at the University of Chicagos School of Medicine and Branch Chief, Diagnostic Development Branch at the National Human Genome Research Institute. David is board-certified by the American Board of Medical Genetics and Genomics as a clinical laboratory geneticist and is a highly accomplished researcher, authoring over 300 peer-reviewed publications. He completed his undergraduate work at Tulane University and his Ph.D., in psychology (behavioral genetics) at The University of Texas at Austin.

About Dascena

Dascena is developing machine learning algorithms to enable early disease intervention and improve care outcomes for patients. For more information, visit dascena.com. Follow us on LinkedIn.

View post:
Dascena Strengthens Executive Leadership Team with Key Appointments and Promotion - Business Wire

This entry was posted on February 7, 2021 at 3:52 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |